Does progesterone prophylaxis to prevent preterm labour improve outcome? (OPPTIMUM)

使用黄体酮预防早产是否可以改善结局?

基本信息

  • 批准号:
    G0700452/1
  • 负责人:
  • 金额:
    $ 279.03万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2008
  • 资助国家:
    英国
  • 起止时间:
    2008 至 无数据
  • 项目状态:
    已结题

项目摘要

Preterm delivery is the biggest single cause of death and disability amongst babies born in the UK. At present, no drug treatment has been demonstrated to improve the outcome for babies by preventing the onset of preterm labour. It has recently been shown that a natural hormone called progesterone may reduce the risk of preterm delivery by around 50%. In the proposed study, we will confirm or refute this effect on preterm delivery and more importantly determine whether it improves the outcome for the baby and child. Pregnant women at high risk of preterm delivery who agree to take part will be given either a progesterone or a placebo (dummy) pessary daily from 22-24 until 34 weeks of pregnancy. We will record when the woman gives birth, whether the baby survives, and if so its immediate health (including any brain damage or lung disease) and health at two years of age using a developmental assessment scale. We will also calculate the costs of NHS treatment. We hope to show that progesterone treatment reduces the risk of preterm birth, that it improves baby’s immediate health, it is associated with improved thinking ability of the child at two years, and it reduces NHS costs overall.
早产是英国出生婴儿死亡和残疾的最大单一原因。目前,没有药物治疗已被证明可以通过预防早产的发生来改善婴儿的结局。最近有研究表明,一种名为孕酮的天然激素可以将早产的风险降低约50%。在拟议的研究中,我们将证实或反驳这种对早产的影响,更重要的是确定它是否改善了婴儿和儿童的结局。同意参加研究的早产高风险孕妇将在妊娠22-24周至34周期间每天接受黄体酮或安慰剂(模拟)阴道栓。我们将记录妇女何时分娩,婴儿是否存活,如果存活,则使用发育评估量表记录其立即健康状况(包括任何脑损伤或肺部疾病)和两岁时的健康状况。我们还将计算NHS治疗的费用。我们希望证明黄体酮治疗可以降低早产的风险,改善婴儿的即时健康,与儿童2岁时思维能力的提高有关,并降低NHS的整体成本。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jane Norman其他文献

Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT
  • DOI:
    10.1016/j.ijgo.2015.02.008
  • 发表时间:
    2015-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Peter von Dadelszen;Laura A. Magee;Beth A. Payne;Dustin T. Dunsmuir;Sharla Drebit;Guy A. Dumont;Suellen Miller;Jane Norman;Lee Pyne-Mercier;Andrew H. Shennan;France Donnay;Zulfiqar A. Bhutta;J. Mark Ansermino
  • 通讯作者:
    J. Mark Ansermino
Improvement in Lymphoma CAR-T Outcomes over Time in the UK - CAR-T Learning Curve or Better Bridging?
  • DOI:
    10.1182/blood-2022-159217
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Stephen Boyle;Robin Sanderson;Maeve A. O'Reilly;Tobias F. Menne;Jane Norman;Adrian Bloor;Sanne Lugthart;Sridhar Chaganti;Carlos Gonzalez-Arias;Ceri Jones;Anne-Louise Latif;Reuben Benjamin;Piers Patten;Deborah Yallop;Victoria Potter;Claire Roddie;Andrea Kuhnl
  • 通讯作者:
    Andrea Kuhnl
A systematic review of risk assessment strategies for populations at high risk of engaging in violent
对参与暴力高风险人群的风险评估策略进行系统审查
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    R. Whittington;Jc Hockenhull;J. Mcguire;M. Leitner;W. Barr;M. Cherry;R. Flentje;B. Quinn;Y. Dundar;R. Dickson;Whittington R;Hockenhull Jc;Barr W Cherry;Ken Stein;Martin Ashton;Matthias Beck;Aileen Clarke;Peter Davidson;Elaine Mccoll Director;William Mcguire;Geoffrey Meads;Jane Norman;John Powell;James Raftery;Helen Roberts;Helen Snooks
  • 通讯作者:
    Helen Snooks
Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
  • DOI:
    10.1182/blood-2024-200738
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Andrea Kuhnl;Amy A Kirkwood;Claire Roddie;Caroline Besley;Jane Norman;Ben Uttenthal;Frances Seymour;Andrew J. Davies;Wendy Osborne;William Townsend;Emil Arjun Kumar;Amrith Mathew;Carlos Gonzalez Arias;Ceri Jones;Aikaterini Panopoulou;Ahmed Abdulgawad;Edward Bataillard;Pierre McCarthy;Nicolas Martinez-Calle;Vaishali Dulobdas
  • 通讯作者:
    Vaishali Dulobdas
<strong>ABO blood group antigens and preterm birth risk</strong>
  • DOI:
    10.1016/j.jri.2023.104083
  • 发表时间:
    2023-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Katherine Mountain;David MacIntyre;Denise Chan;Alice Hyde;James Pasint-Magyar;Yun Lee;Richard Brown;Anna David;Anne Dell;Ten Feizi;Stuart Haslam;Yan Liu;Holly Lewis;Jane Norman;Sarah Stock;Tiong Teoh;Vasso Terzidou;Samit Kundu;Phillip Bennett;Lynne Sykes
  • 通讯作者:
    Lynne Sykes

Jane Norman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jane Norman', 18)}}的其他基金

MICA: A pragmatic approach to the prevention of gestational diabetes and pre-eclampsia in obese pregnant women in resource poor settings
MICA:资源匮乏地区肥胖孕妇预防妊娠期糖尿病和先兆子痫的实用方法
  • 批准号:
    MR/R019142/1
  • 财政年份:
    2018
  • 资助金额:
    $ 279.03万
  • 项目类别:
    Research Grant
iNKT cells as drivers for preterm labour
iNKT 细胞作为早产的驱动因素
  • 批准号:
    MR/L002647/1
  • 财政年份:
    2013
  • 资助金额:
    $ 279.03万
  • 项目类别:
    Research Grant
Does metformin reduce excess birthweight in offspring of obese pregnant women?
二甲双胍是否可以减少肥胖孕妇的后代的超重出生体重?
  • 批准号:
    MC_G1002463
  • 财政年份:
    2010
  • 资助金额:
    $ 279.03万
  • 项目类别:
    Intramural

相似海外基金

Effects of PrEP Drugs on Female Genital HIV Infection and Women's Reproductive Health
PrEP药物对女性生殖器HIV感染及妇女生殖健康的影响
  • 批准号:
    10703238
  • 财政年份:
    2022
  • 资助金额:
    $ 279.03万
  • 项目类别:
Effects of PrEP Drugs on Female Genital HIV Infection and Women's Reproductive Health
PrEP药物对女性生殖器HIV感染及妇女生殖健康的影响
  • 批准号:
    10548694
  • 财政年份:
    2022
  • 资助金额:
    $ 279.03万
  • 项目类别:
Perceptions of Multipurpose Prevention Technologies Aimed at HIV/STI/unintended pregnancy among African-American Women in the Deep South
对针对南方腹地非裔美国妇女艾滋病毒/性传播感染/意外怀孕的多用途预防技术的看法
  • 批准号:
    10534239
  • 财政年份:
    2020
  • 资助金额:
    $ 279.03万
  • 项目类别:
Perceptions of Multipurpose Prevention Technologies Aimed at HIV/STI/unintended pregnancy among African-American Women in the Deep South
对针对南方腹地非裔美国妇女艾滋病毒/性传播感染/意外怀孕的多用途预防技术的看法
  • 批准号:
    10415831
  • 财政年份:
    2020
  • 资助金额:
    $ 279.03万
  • 项目类别:
Feminizing Sex Hormones Impact on PrEP Pharmacology in Transgender Women
女性化性激素对跨性别女性 PrEP 药理学的影响
  • 批准号:
    9910363
  • 财政年份:
    2019
  • 资助金额:
    $ 279.03万
  • 项目类别:
Developmental Pharmacology of Antiretroviral Metabolism in Mucosal Tissues
粘膜组织中抗逆转录病毒代谢的发育药理学
  • 批准号:
    9244420
  • 财政年份:
    2017
  • 资助金额:
    $ 279.03万
  • 项目类别:
Effects of contraceptive ring on vaginal microbiota, HIV shedding and local immunity
避孕环对阴道微生物群、HIV 排出和局部免疫的影响
  • 批准号:
    9330194
  • 财政年份:
    2013
  • 资助金额:
    $ 279.03万
  • 项目类别:
AIDS Malignancy Clinical Trials Consortium
艾滋病恶性肿瘤临床试验联盟
  • 批准号:
    7689546
  • 财政年份:
    2006
  • 资助金额:
    $ 279.03万
  • 项目类别:
AIDS Malignancy Clinical Trials Consortium
艾滋病恶性肿瘤临床试验联盟
  • 批准号:
    7689549
  • 财政年份:
    2006
  • 资助金额:
    $ 279.03万
  • 项目类别:
AIDS Malignancy Clinical Trials Consortium
艾滋病恶性肿瘤临床试验联盟
  • 批准号:
    7689545
  • 财政年份:
    2006
  • 资助金额:
    $ 279.03万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了